Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Bevacizumab Stories

2012-01-04 08:52:00

VOORHEES, N.J., Jan. 4, 2012 /PRNewswire/ -- Metastatic breast cancer is an extremely challenging diagnosis. Fortunately, recent advances in treatment, including the development of novel targeted agents, have resulted in improvements in the management of this disease. Because of the rapidly changing treatment milieu for metastatic breast cancer, it is critically important for physicians to understand these most recent advances in treatment in order to optimally treat patients with this...

2011-12-29 09:56:23

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research...

2011-12-29 09:52:39

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK. The findings, published today in the New England Journal of Medicine, report that the drug halted the cancer's return for two months overall. However, for women with the...

2011-12-21 06:24:22

(Ivanhoe Newswire) — Scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. Cancer cells can grow and multiply faster by creating their own blood vessels. Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumor. These proteins are vascular growth factors like VEGF – the target for the anti-cancer drug Avastin. Making these...

2011-12-19 06:00:00

INCLINE VILLAGE, Nev., Dec. 19, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million, as compared with actual results of $76 million for the fourth quarter of 2010, a five percent decrease. Total anticipated revenue for the year ended December 31, 2011 is $361 million as compared with actual results of $345 million for the year ended December 31, 2010, a five...

2011-12-08 12:55:30

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D., director of medical oncology at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011...

Avastin Loses Approval For Breast Cancer Treatment
2011-11-19 06:27:46

The U.S. Food and Drug Administration (FDA) has ruled that the drug Avastin should no longer be used by breast cancer patients because there is no proof that it can prolong their lives and because of the medicine's dangerous side effects. According to the Associated Press (AP), the ruling had been "long expected," but was "sure to disappoint women who say they have run out of other options." The wire service said that FDA Commissioner Dr. Margaret Hamburg said that the decision was a...

2011-11-18 19:37:00

WASHINGTON, Nov. 18, 2011 /PRNewswire-USNewswire/ -- Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer. Terry Kalley, founder of the Freedom of Access to Medicines (FAMEDS), condemned the decision, saying, "While this vote is highly disappointing, it wasn't unexpected, given the FDA's...

2011-11-18 16:56:00

Maintains clearness of vision in those with wet age-related macular degeneration SILVER SPRING, Md., Nov. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) AMD gradually destroys a person's sharp, central vision. It...

2011-11-18 16:51:00

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA( )(aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2...